Metabolic Associated Fatty Liver Disease (MAFLD) is a range of hepatic disorders with progression to steatohepatitis with risk of development of fibrosis, cirrhosis, and hepatocellular carcinoma. MAFLD is strongly related to metabolic disorders of active fatty acids, which seem to be selective according to their specific ligand of G protein-coupled receptors (GPRs) located in immune response cells. An approach to study the pathophysiological mechanisms of MAFLD could be through the expression of active fatty acids ligands. The expression of GPRs is associated with obesity, microbiota environment, and dietary characteristics in patients with MAFLD. More specifically, GPR41, GPR43, GPR20, and GPR120 have been associated with alteration of lipid metabolism in hepatic and intestinal cells, and consequently they have a key role in metabolic diseases. We observed that GPR120 is not expressed in non-overweight/obese patients, regardless of the presence of MAFLD; meanwhile the expression of GPR41 is increased in patients with lean MAFLD. GPRs role in liver disease is intriguing and a field of research opportunity. More studies are necessary to define the role of active fatty acids in the development of metabolic diseases.

代谢相关脂肪肝病 (MAFLD) 是一系列肝脏疾病，可进展为脂肪性肝炎，并有发生纤维化、肝硬化和肝细胞癌的风险。MAFLD 与活性脂肪酸的代谢紊乱密切相关，根据它们位于免疫反应细胞中的 G 蛋白偶联受体 (GPR) 的特异性配体，活性脂肪酸似乎具有选择性。研究 MAFLD 病理生理机制的一种方法可能是通过活性脂肪酸配体的表达。GPRs的表达与MAFLD患者的肥胖、微生物群环境和饮食特征有关。更具体地说，GPR41、GPR43、GPR20 和 GPR120 与肝和肠细胞中脂质代谢的改变有关，因此它们在代谢疾病中起关键作用。我们观察到 GPR120 在非超重/肥胖患者中不表达，无论是否存在 MAFLD；同时GPR41在瘦MAFLD患者中表达增加。GPR 在肝病中的作用很有趣，也是一个研究机会领域。需要更多的研究来确定活性脂肪酸在代谢疾病发展中的作用。